Table 2.
The value of single tumor marker testing in screening for lung cancer in patients with benign lung lesions and healthy individuals.
| SEN | SPE | PPV | NPV | +LR | −LR | Yden | Cutoff | AUC | |
|---|---|---|---|---|---|---|---|---|---|
| Benign lung disease | |||||||||
| CEA | 0.501 | 0.690 | 0.555 | 0.642 | 1.61 | 0.72 | 0.212 | 5.625 | 0.619 |
| CA125 | 0.346 | 0.672 | 0.449 | 0.571 | 1.03 | 0.97 | 0.154 | 54.56 | 0.537 |
| NSE | 0.481 | 0.877 | 0.752 | 0.686 | 3.91 | 0.59 | 0.405 | 13.94 | 0.695 |
| GRP | 0.471 | 0.805 | 0.651 | 0.663 | 2.41 | 0.65 | 0.329 | 90.01 | 0.570 |
| CY211 | 0.511 | 0.519 | 0.451 | 0.579 | 1.06 | 0.94 | 0.232 | 4.49 | 0.538 |
| Healthy | |||||||||
| CEA | 0.500 | 0.890 | 0.836 | 0.616 | 4.54 | 0.56 | 0.448 | 2.335 | 0.771 |
| CA125 | 0.340 | 0.970 | 0.927 | 0.573 | 11.33 | 0.68 | 0.483 | 14.61 | 0.729 |
| NSE | 0.483 | 0.880 | 0.812 | 0.613 | 4.02 | 0.58 | 0.362 | 16.42 | 0.667 |
| GRP | 0.469 | 0.936 | 0.891 | 0.614 | 7.32 | 0.56 | 0.395 | 48.55 | 0.663 |
| CY211 | 0.510 | 0.857 | 0.798 | 0.612 | 3.56 | 0.57 | 0.417 | 3.62 | 0.713 |
SEN: sensitivity; SPE: specificity; PPV: positive predictive value; NPV: negative predictive value; +LR: positive likelihood ratio; −LR: negative likelihood ratio; and Yden: Youden index.